Hospital Medicine

Investigators test methods of incorporating smaller, localized datasets to improve influenza outbreak forecasts and increase community preparedness.

A recent study disproves a long-held belief that annual flu shots had a negative impact on vaccine effectiveness.

The 4th generation VITROS HIV Combo test has been approved for use with the VITROS ECi/ECiQ Immunodiagnostic System.

Investigators indicated areas of potential improvement for the treatment of new or recurrent C difficile infection.

The septic shock therapy was approved by the FDA last December. How has it fared in its first year of real-world clinical use?

Emapalumab (Gamifant) is the first FDA-approved treatment for a rare condition that causes life-threatening hyper-inflammation.

HRS-1 is a rare, acute complication of liver cirrhosis characterized by life-threatening and rapid progression that can end in renal failure. Terlipressin, a vasopressin analogue, could become the first therapy approved for the treatment of HRS-1 in the US.

The FDA has expanded Novartis’ eltrombopag (Promacta) to include first-line treatment for adults and pediatric patients aged 2 years and older with severe aplastic anemia (SAA) in combination with standard immunosuppressive therapy (IST).

The antibacterial therapy has been indicated for forms of the disease driven by E. coli.

In analysis, the therapy plus standard immunosuppressive therapy resulted in a complete response rate 27% greater than that historically observed in patients treated with lone IST, over 6 months.

The influenza virus has shown resistance to a promising new drug—favipiravir—that is being developed for widespread use, including in a flu pandemic.

A popularizing procedure among stroke centers was the basis of clinical research for the medical center, and is now improving in practice.

How surgeons' duties surround the entire invasive process, and therefore make them something closer to specialists.

In addition to a 25% reduction of risk of future cardiovascular events, icosapent ethyl (Vascepa) lowered the risk of cardiovascular death by 20%.

Ezetimibe 10 mg/day significantly reduced the incidence of atherosclerotic cardiovascular events in elderly patients with high LDL cholesterol compared to control.

Treatment regimens comprised of DCV+SOF±RBV and VEL/SOF+RBV offer similar cure rates among HCV patients with genotypes 2 and 3.